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Epidemiology and Ecology of 
Leishmaniasis
Tonay Inceboz
Abstract
Leishmaniasis is the third most important vector-borne disease after malaria 
and lymphatic filariasis. It is common disease in all over the world. The vector for 
leishmaniasis is Phlebotomus and there have found around 20 different types of this 
vector. There are different clinical forms under the name of leishmaniasis such as 
kala-azar, dum-dum fever, white leprosy, espundia, pian bois, chiclero’s ulcer, uta. 
Environmental factors leading to climate changes and global warming are major 
risk factors for the spreading of the disease. Leishmania spp. to prevent the spread 
of the definitive host and intermediate hosts is difficult compared to Plasmodium 
spp. Therefore; leishmaniasis disease will retain its importance for many years.
Keywords: leishmaniasis, neglected tropical diseases, vector-borne disease, 
epidemiology, ecology
1. Introduction
This fact is mainly due to the presence of many different species of leishmania, 
its vectors and hosts in different parts of the world. More than 20 pathologic species 
of leishmania and over 30 species of Phlebotomus—the vector- are known worldwide 
(Figure 1, Table 1).
On the other hand, deterioration of the eco-systems by human beings also 
contribute to the spread of the disease in the world.
Leishmaniasis has four clinical forms. These are cutaneous leishmaniasis (CL, 
local—LCL or diffuse—DCL), mucocutaneous leishmaniasis (MCL), visceral 
leishmaniasis (VL), post-kala-azar dermal leishmaniasis (PKDL), (Table 1).
Figure 1. 
Taxonomy of leishmania family [1].
Current Topics in Neglected Tropical Diseases
2
In this section we aimed to reveal the epidemiologic analysis of different types of 
leishmaniasis in all over the world in every aspect.
2. Geographic distribution and incidence
Leishmaniasis, as being one of the world’s most neglected diseases, affects 
mainly the poor, developing countries; 350 million people are thought to be at risk 
of contracting leishmaniasis. It is estimated that approximately 12 million men are 
ill and 2 million new cases occur annually [1, 2].
With new epidemics occurring in endemic areas and the spread of leishmani-
asis to previously free areas because of migration, tourism, and military activities. 
Leishmaniasis is a disease of the poor, occurring mostly in remote rural villages with 
poor housing and little or no access to modern health-care facilities. In endemic 
areas, diagnosis of any form of leishmaniasis puts a huge financial strain on an 
already meagre financial resource at both the individual and community levels [3].
Visceral leishmaniasis: approximately 90% of new cases occur in the world’s 
cases of India, Bangladesh, Nepal, Ethiopia, Sudan and Brazil are seen. The annual 
number of cases worldwide has been estimated to be visceral leishmaniasis, 
between 200,000 and 400,000. The two important causative agents of visceral 
leishmaniasis (VL), namely Leishmania (L) donovani and L. infantum, cause signifi-
cant health problems [1, 4].
Visceral leishmaniasis (VL), also known as “kala azar,” is caused by parasites of 
the L. donovani complex in some parts of the world. The L. donovani complex can be 
found throughout Asia, North Africa, Latin America and Southern Europe, affect-
ing mostly vulnerable and uncared populations. As being the most severe form, VL 
is almost always fatal if left untreated. It is characterized by undulating fever, loss 
Subgenus L. (Leishmania) L. (Leishmania) L. (Viannia) L. (Viannia)
Old World L. donovani L. major
L. infantum L. tropica
L. killickia
L. aethiopica
L. infantum
New World L. infantum L. infantum L. braziliensis L. braziliensis
L. mexicana L. guyanensis L. panamensis
L. pifanoia L. panamensis
L. venezuelensis L. shawi
L. garnhamia L. naïffi
L. amazonensis L. lainsoni
L. lindenbergi
L. peruviana
L. colombiensisb
Principal tropism Viscerotropic Dermotropic Dermotropic Mucotropic
aSpecies status is under discussion.
bTaxonomic position is under discussion.
Table 1. 
Leishmania found in humans [1].
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of weight, splenomegaly, hepatomegaly and/or lymphadenopathies and anemia 
L. infantum, the other causative agent of VL, is found in Southern Europe, North 
Africa and West and Central Asia [1, 5].
Post-kala-azar dermal leishmaniasis (PKDL) is another clinical composition of 
kala azar and it is seen in all areas endemic for L. donovani. It especially comments 
in East Africa and on the Indian subcontinent with a prevalence of 50 and 10%, 
respectively [1, 6].
Cutaneous leishmaniasis: approximately 90% of the world’s cases of 
Afghanistan, Pakistan, Sudan, Syria, Saudi Arabia, Algeria, Iran, Iraq, is seen in 
Brazil and Peru. The annual number of cases worldwide has been estimated to be 
visceral leishmaniasis, cutaneous leishmaniasis: between 700,000 and 1.2 million 
[1]. Old World species: L. major, L. infantum, and L. tropica, New World species, 
such as, L. amazonensis, L. chagasi, L. mexicana, L. viannia (V) naiffi, L. (V.)  
braziliensis, and L. (V.) guyanensis [6, 7]. Antroponotic cutaneous leishmaniasis 
(ACL) is caused by most Leishmania species, occur in most subtropical and tropical 
regions (for example, L. major from Africa and Asia, and L. mexicana from Central 
and South America), and by many species in the subgenus Viannia, which are 
limited to Latin America (for example, L. (V) brasiliensis) [6].
Old World cutaneous leishmaniasis caused by L. tropica (seen particularly in 
the Mediterranean Basin, the Middle East, Pakistan and India) and L. infantum, 
(found sporadically in the Middle East, South Russia, and rural regions of Africa). 
New World cutaneous leishmaniasis, caused by L. brazilensis and L. mexicana is 
seen in Mexica and South America. Leishmaniasis exists on every continent except 
Australia, the Pacific Islands and Antarctica. The parasites that cause leishmaniasis 
are found in 98 countries around the world [7].
L. tropica, L. major, L. aethiopica and L. infantum causes Old World cutaneous leish-
maniasis. Leishmania tropica is mainly seen in urban areas and causes ACL. Related 
vectors are Phlebotomus sergenti and Phlebotomus papatasii. Lesions are generally dry 
and remain without ulceration. During the course lesions change to papules [1, 8].
L. tropica is found in urban areas. It causes ACL via the vectors Phlebotomus 
sergenti and Phlebotomus papatasii. The lesions are dry and stay for a long period of 
time without ulceration. Thereafter, painless lesions as papules, tubercles or nodules 
subside without scarring in 9–12 months [8].
L. major infections generally cause wet lesions in habitants of rural areas. 
Incubation period is less than 4 months. Lesions are usually seen on the legs. They 
start as acute papillary infection in the bite area and advances into pustular ulcers 
in 1–3 weeks. The infection is categorized as “zoonotic cutaneous leishmaniasis 
(ZCL)” due to the transmission to rodents, dogs via Phlebotomus papatasi [9].
L. infantum often causes small (0.5–1 cm), solitary ulcers on the face [10].
L. aetropica lesions are seen in the mouth and nose with local or wide spread 
dermal involvement. Lesions rarely become ulcerated. Healing may take 1–3 years 
or more [11].
L. braziliensis, L. mexicana, L. amazoensis, L. guyanensis, L. panamensis and L. 
peruviana cause New World cutaneous leishmaniasis [8, 12].
The disease caused by L. braziliensis is named “espundia.” The infection leads 
to metastatic lesions, damages and deformation of the cartilage and soft tissues by 
affecting buccal and nasal mucosa [13].
L. mexicana causes usually solitary, painless lesions in the pinna. It leads to 
chronic lesions in the pinna called “chiclero’s ulcer” [14].
L. guyanensis infection is consisted of flat ulcerative plaques with leakage in 
whole body. The lesion is called “pianbois” in Uruguay and Venezuella [15].
L. amazonensis causes solitary or multiple lesions with rarely spontaneous remis-
sion. It is rare in humans [8].
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L. peruviana infection causes solitary or multiple painless dermal lesions they 
usually subsided spontaneously in 4–5 months. This infection is called uta [16].
Lesions of L. panamensis are ulcers without spontaneous improvement the 
reservoirs are dogs and monkeys [12].
L. venezuelensis generally causes solitary painless nodular lesion. [12, 17].
L. garnhami usually causes solitary or multiple lesions and may spontaneously be 
healed in 6 months [12].
The Eastern Hemisphere (Old World): leishmaniasis is found in some parts of 
Asia, the Middle East, Africa (especially in the tropical region and North Africa), 
and Southern Europe.
The Western Hemisphere (New World), leishmaniasis is found in some parts of 
Mexico, Central America, and South America. It is not found in Chile or Uruguay.
Leishmaniasis is seen in most tropical and subtropical regions with climate, 
mainly in South and Central America, Africa, Asia, and Southern Europe. The 
leishmaniasis is considered as one of the neglected tropical diseases (NTD) 
(Figures 2 and 3) [18].
Figure 3. 
World CL distribution in the last 10 years [19].
Figure 2. 
World VL distribution in the last 10 years [19].
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3. Epidemiology of leishmaniasis according to vector
a. Phlebotomus spp. (sandfly). (Old World).
b. Lutzomyia spp. (New World).
Humidity and moisture, whether from rainfall or in the soil, have often been 
identified as important for the sandfly, with humidity influencing breeding and 
resting [6].
Sandflies belonging to either Phlebotomus spp. (Old World) or Lutzomyia spp. 
(New World) are the primary vectors; domestic dogs, rodents, sloths, and opos-
sums are amongst a long list of mammals that are either incriminated or suspected 
reservoir hosts [1, 21, 22]. Most of its foci in the Old World have a Mediterranean 
climate and sand fly vectors, usually Phlebotomus (Larroussius) species, Phlebotomus 
species (P. papatasi, P. sergenti, Phlebotomus alexandri, P. tobbi, Phlebotomus syriacus, 
Phlebotomus neglectus, Phlebotomus perfiliewi, Phlebotomus galilaeus, Phlebotomus 
transcaucasicus, and Phlebotomus halepensis) two Sergentomyia species (Sergentomyia 
theodori and Sergentomyia dentata), (Phlebotomus ariasi and Phlebotomus perniciosus, 
Phlebotomus longicuspis) can diapauses for human visceral leishmaniasis [21–24].
In contrast to malaria, there is little evidence for the effect of vector control in 
leishmaniasis because terrestrial habitat of Phlebotomus is mostly unknown.
4. Host
4.1 Human
Leishmania species are transmitted to human via vectors, blood transfusion, 
organ transplantation or vertically via transplacental route. Other factors that cause 
the transmission of the disease are contact with contaminated materials or needle 
stick injuries in the labs [25–27].
Leishmania-infected humans especially in poor socioeconomic conditions play 
a pivotal role as a reservoir in transmission of the agent to vectors or to other hosts. 
In another words, one can say that human beings contribute the disease transmis-
sion by themselves [26, 27]. Poor living conditions in adobe, wooden houses, barns 
create a tendency towards an increase of vectors [27–29].
In all three clinical types of Leishmania spp., antimonials (sodium stibogluconate 
[SSG]), miltefosin (MIL), amfoterisin B (AmB) veparomomisin (PMM)) are being 
used [30]. Children and people with immune suppression, HIV infection or malig-
nant diseases cause rapid spread of leishmaniasis. Apart from these, undiagnosed or 
untreated infected people create an important risk factor. Especially drug resistance 
and high expense of the medication cause insufficient treatment [27–29]. The first 
drug resistance was reported in VL treatment against SSG and against MIL, in India 
and Nepal, respectively [31–33]. Later, resistance against MIL was also reported in 
one patient with HIV and another two patients with Indian origin [34, 35].
Verma et al. showed that the effectiveness of PMM was decreased by 6 times for 
the promastigote forms of L. donavani [36]. Invasion of macrophages by PMM-R 
parasites led to increased nitric oxide (NO), whereas the levels of reactive oxygen 
species (ROS) remained unchanged. This finding shows resistance of Leishmania 
spp. against PMM [36]. Similarly, Deep et al., reported high recurrence rates in 
patients with VL and PKDL when treated with MIL [37].
In conclusion, due to immune problems of the patient, co-existence of other dis-
eases, inappropriate use of the drugs during the medical treatment of leishmaniasis, 
“drug resistance” may occur via gene over-expression, deletion, single nucleotide 
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Leishmaniaspecies Disease Countries (suspected) Landscapes Reservoir hosts Vector
Old World
L. donovani AVL, DCL, 
CL
Northeast India, Nepal, Bangladesh, (Bhutan), 
Sri Lanka, Republic of China, Sudan, Ethiopia, 
(Chad), (Yemen), Kenya
Rural, peri-domestic Human anthroponosis P. (Eu.) argentipes, P. (La.) orientalis, 
P. (Sy.) martini
L. donovani AVL People’s Republic of China Rural, peri-domestic Unknown P. (Pa.) alexandri, P. (Ad.) species
L. donovanib (L. 
archibaldi)
AVL, ZVL, 
ML
Sudan, Ethiopia, (Chad), (Yemen) Rural, Acacia—
Balanites forest
Human anthroponosis P. (Larroussius) orientalis
L. donovanib (L. 
archibaldi)
AVL, DCL Sudan, Ethiopia, Kenya, (Uganda) Rural, 
savannatermite 
mounds
Human anthroponosis P. (Sy.) martini
L. infantum ZVL, ZCL Med Europe, North Africa, Southwest Asia, 
People’s Republic of China
Rural, peri-domestic Domestic dog, wild 
canids, domestic cat
P. (La.) ariasi, perniciosus
L. infantumc (L. chagasi) VL, CL Latin America: not Peru or Guianas Rural, peri-domestic Domestic dog, wild canids Lu. (L.) longipalpis
L. major ZCL North Africa, Ethiopia, Kenya, Sudan, Meadle 
Asia India
Peri-domestic Human anthroponosis P. papatasi, P. duboscqi
Le. (Le.) tropica ACL North Africa, Middle East, Iran, Afghanistan Urban Peridomestic, including 
suburbs; human
P. (Paraphlebotomus) sergenti
Le. (Le.) tropicac (Le. 
(Le.) killicki)
ZCL North Africa, MiddleEast, Sub-Saharan Africa Rural Rockyarid; hyraxes, 
Rodents
P. (Adlerius) arabicus P. (La.) 
guggisbergi
Le. (Le.) aethiopica; ZCL,DCL, 
ML
Ethiopia, Kenya Rural, Rocky 
highlands
Hyraxes P. (La.) longipes P. (La.) pedifer
New World
Leishmania (Leishmania) 
infantum
ZVL, ZCL Latin America: not Peru, Guianas Peridomestic, 
including suburbs
Domestic dog Lutzomyia (Lutzomyia) longipalpiss.l.
Leishmania(Viannia) 
braziliensis
ZCL, ML East of Andes: not Guyana, Suriname Peridomestic, 
silvatic
Rodents, marsupials, dog L. (Psychodopygus) wellcomei L. 
(Nyssomyia) neivai L. (Ny.) whitmani
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Leishmaniaspecies Disease Countries (suspected) Landscapes Reservoir hosts Vector
Le. (V.) braziliensis ZCL, ML West of Andes, northern Venezuela: not El 
Salvador
Peridomestic, 
silvatic
Rodents, marsupials, dog L. (Pifanomyia) ovallesi
Le. (V.) peruviana ZCL, ML Peru Peridomestic, 
silvatic
Rodents, marsupials, dog L. (He.) peruensiss.l. L. (Pf.) 
verrucarums.l.
Le. (V.) guyanensis ZCL, ML East of Andes: not Paraguay Silvatic Arboreal edentates, others L. (Ny.) umbratilis
Le. (V.) panamensis ZCL, ML West of Andes, northern Venezuela: not 
Mexico, Belize, El Salvador
Silvatic Arboreal edentates, others L. (Ny.) trapidoi L. (Ny.) ylephiletor 
L. (Ny.) edentula L. (Tricholateralis) 
gomezi
Le. (V.) shawi ZCL Brazil Silvatic Arboreal L. (Trichophoromyia) ubiquitalis L. 
(Pf.) nuneztovari
Le. (V.) lainsoni ZCL Bolivia, Peru, Brazil, French Guiana, Suriname Silvatic Rodent Agouti paca L. (Trichophoromyia) ubiquitalis L. 
(Pf.) nuneztovari
Le. (V.) colombiensis ZCL Panama, Colombia, Venezuela Silvatic Choloepushoffmanni L. (He.) hartmanni
Le. (V.) naiffi ZCL Brazil, French Guiana, Panama Silvatic Dasypusnovemcinctus L. (Ps.) ayrozai and other species L. 
(Ny.) trapidoic
Le. (Le.) amazonensis ZCL, DCL East of Andes: not Guyana, Paraguay Silvatic, non-climax 
forest
Terrestrial rodents, 
Marsupials
L. (Ny.) flaviscutellata
Le. (Le.) mexicana ZCL, DCL, 
ML
West of Andes, southern United States: not 
Peru
Silvatic, non-climax 
forest
Terrestrial rodents, 
Marsupials
L. (Ny.) olmecaolmeca
Le. (Le.) venezuelensis ZCL, DCL Northern Venezuela Silvatic Unknown L. (Ny.) olmecabicolor
Abbreviations: TC, transmission cycle; A, anthroponotic; Z, zoonotic; V, visceral; C, cutaneous; M, mucosal; D, diffuse; L, leishmaniasis. P., Phlebotomus; Pa., Paraphlebotomus; Pf., Pifanomyia; Sy., 
Synphlebotomus La., Larroussius; Lu., Lutzomyia.
Table 2. 
Disease types and transmission cycles of leishmaniasis worldwide [6, 20, 21].
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polymorphisms generating stop codons or amplification of sets of genes [38–40]. 
This very important for epidemiological standpoint and thus proper use of drugs 
when needed should be stressed, and also new drug formulations and/or vaccine 
should be investigated.
Technological advances let the people travel all over the world. This may cause 
vectored spread or spread directly by infected people [41].
4.2 Dogs
Dogs are very important in terms of the epidemiology of leishmaniasis. All 
forms of leishmaniasis namely cutaneous, mucocutaneous and visceral types may 
be found in dogs. Since the infected dogs are important reservoir of the disease, 
their controls and treatments are mandatory for the disease control. Dogs as pets 
are being controlled by vets however stray or wild dogs, fox species like Lycalopex 
vetulus [42], Cerdocyonthous [43] may cause outbreaks. Dogs are natural hosts 
for L. infantum, L. chagasi, L. tropica and L. peruviana as well as being infected 
by them. Especially they are endemic in dogs in Mediterranean region, Asia and 
Latin America. Leishmania infantum is the causative agent of visceral leishmani-
asis and it is prevalent especially in Mediterranean region. Vectors for this type are 
Phlebotomus ariasi, P. major, P. perniciosus, P. longicuspis, P. chiensis, P. mongolensis, 
P. papatasi [44, 45]. In the same region, the causative agent of zoonotic cutaneous 
leishmaniasis is L. tropica and the vectors are P. perfilievi, P. papatasi and P. sergenti 
[1, 46]. In South America, the causative agent of canine cutaneous leishmaniasis is 
L. chagasi and the vectors are Lu. longipalpalis, Lu. evansi, Lu. gomezi [1].
4.3 Rodents
Comparing to dogs, eradication of the infectious agent of leishmaniasis from the 
rodents is more difficult and even sometimes impossible.
Different rodents such as Didelphis albiventris (opossum), Mus musculus (domes-
tic mouse), Microtus socialis, Rattusrattus (black rat), Cercomys cunicularius (wild 
rat), Mesocricetus auratus (Syrian hamsters) in America, Africa and Asia lead to 
spread of leishmaniasis [47–51].
Phlebotomus papatasi, vector of L. tropica, transmitted cutaneous leishmani-
asis to small rodents such as Psammomys obesus (Israel), Meriones crassus (Israel), 
Meriones libycus (Iran), Rhombomys opimus (Iran), Rhombomys opimus (Iran), 
Meriones sacramenti (Egypt) [9].
Rattus rattus and Rattus norvegicus have been found naturally infected with L. 
infantum in the Mediterranean and in Next Orient endemic areas (Table 2) [49, 52, 53].
5. Transmission cycle
There are two different types of transmission;
1. In many geographic areas, infected people are not needed to sustain the 
transmission cycle of the parasite in nature; transmission cycle continue 
via the infected animals (rodents or dogs, felines). Leishmania infection in 
reservoir animals are specifically named; if it is in dogs, it is named as canine 
leishmaniasis whereas in cats, it is called feline leishmaniasis dogs species of 
Leishmania species in the reservoir in animals, canine leishmaniasis, which is 
in feline called leishmaniasis. L. infantum is the most common and important 
cause of canine leishmaniasis worldwide. The zoonotic transmission of L. 
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infantum, from canine to humans, is not only in the Mediterranean region 
where it may have originated, but also it may be found in many of the drier 
regions of Latin America. Leishmania species reported from dogs include 
L. mexicana, L. donovani, and L. braziliensis. These Leishmania species are 
occasionally reported from the cats. Cats are at risk of infection especially in 
areas where these parasites are endemic [6, 54, 55].
2. In some parts of the world, infected people are needed to sustain the cycle; this 
kind of transmission (human—Phlebotomus—human) is called anthroponotic 
transmission.
Full knowledge on these two transmission cycles is very important in effective 
prevention of leishmaniasis [54, 55].
6. Effect of deteriorated eco-system on spread of leishmaniasis
Unlike other parasites, it is extremely difficult to eradicate whole kinds of spe-
cies of Leishmania in nature. This is contrary to some other parasites. As example 
Plasmodium vivax is specific to human, thus it can be eradicated by vector control. 
However, this is not the case for Leishmania spp. [54, 55].
There are many check points to establish the control of the disease. Firstly, all 
patients with leishmaniasis should be properly treated. Leishmania transmission is 
dependent on the togetherness of contaminated sandflies with the reservoir hosts, 
and humans. Additionally, climatic and environment factors are important, too.
As the development of chemical insecticides use such as dichlorodiphenyltri-
chloroethane (DDT) against mosquito was a key component of the eradication, 
similarly they were proposed to have an effect on the sandflies, vectors of visceral 
leishmaniasis [56–58]. Since DDT use is found to be harmful to the environment 
and people, its use is prohibited by the World Health Organization [59]. At the 
moment there isn’t any strategy to control Phlebotomine by using insecticides by 
governments [60, 61]. Preliminary experiments for developing a vaccine against 
Leishmania spp. was reported [62]. However, the vaccine did not appear to protect 
against visceral leishmaniasis [63]. fucose-mannose ligand from an extract of 
L. donovani has been used in conjunction with a saponin adjuvant in attempts to 
vaccine [64]. Further studies are needed to develop an effective vaccine against 
leishmaniasis.
7. Summary
Leishmaniasis is still an important parasite disease in all over the world. The 
reasons are presence of many different species of Leishmania, and their ability 
to survive in many different organisms, such as vectors, dogs, rodents, humans. 
Leishmania spp. may cause different clinical scenarios by affecting different tissues 
and organs. As eukaryotic cells, Leishmania spp. can survive in the immune system 
of the most advanced organism, human. Presence of amastigote forms even in the 
hosts’ defensive cells shows the strength of the parasite.
Leishmaniasis is an important public health problem. Thus, relevant public 
health policies such as education of the people especially in endemic areas, multi-
disciplinary approach, diagnosis, treatment will be helpful in the elimination of the 
disease. Additionally, further epidemiological studies as well as vaccination studies 
will continue to strive for eradication.
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Current Topics in Neglected Tropical Diseases
Author details
Tonay Inceboz
Department of Parasitology, Medical Faculty, Dokuz Eylul University, Izmir, 
Turkey
*Address all correspondence to: tonay.inceboz@gmail.com
11
Epidemiology and Ecology of Leishmaniasis
DOI: http://dx.doi.org/10.5772/intechopen.86359
References
[1] WHO Expert Committee. Control 
of the leishmaniasis: Report of a 
meeting of the WHO Expert Committee 
on the Control of Leishmaniases, 
Geneva, 2010; 22-26 March. WHO 
Technical Report Series; 949:1-186. 
Available from: http://apps.who.int/
iris/bitstream/10665/44412/1/WHO_
TRS_949_eng.pdf
[2] Ghaffar A. Microbiology and 
Immunology Online, Parasıtology—
Chapter Two Blood and Tıssue 
Protozoa Part 1 Trypanosomiasıs and 
Leishmaniasis. 2013. Available from: 
http://www.microbiologybook.org/
parasitology/blood-proto.htm
[3] Okwor I, Uzonna J. Social 
and economic burden of human 
leishmaniasis. The American Journal 
of Tropical Medicine and Hygiene. 
2016;94(3):489-493. DOI: 10.4269/
ajtmh.15-0408
[4] Zijlstra EE. Visceral 
leishmaniasis: A forgotten epidemic. 
Archives of Disease in Childhood. 
2016;101(6):561-567
[5] Gouzelou E, Haralambous C, 
Antoniou M, Christodoulou V, 
Martinković F, Živičnjak T, et al. 
Genetic diversity and structure in 
Leishmania infantum populations 
from southeastern Europe revealed 
by microsatellite analysis. Parasites 
& Vectors. 2013;6:342. DOI: 
10.1186/1756-3305-6-342
[6] Ready PD. Biology of phlebotomine 
sand flies as vectors of disease agents. 
Annual Review of Entomology. 
2013;58:227-250. DOI: 10.1146/
annurev-ento-120811-153557
[7] de Vries HJ, Reedijk SH, Schallig 
HD. Cutaneous leishmaniasis: Recent 
developments in diagnosis and 
management. American Journal of 
Clinical Dermatology. 2015;16:99-109. 
DOI: 10.1007/s40257-015-0114-z
[8] Krotoski MJ. Medical Parasitology. 
8th ed. London: W.B. Saunders 
Company; 1999. pp. 147-154
[9] Klaus SN, Frankenburg H, Ingber 
A. Epidemiology of cutaneous 
leishmaniosis. Clinical Dermatology. 
1999;17:257-260. DOI: 10.1016/
S0738-081X(99)00043-7
[10] Bensaid M, Guerbouj S, Saghrouni 
F, Fathallah-Mili A, Guizani I. 
Occurrence of Leishmania infantum 
cutaneous leishmaniasis in Central 
Tunisia. Transactions of the Royal 
Society of Tropical Medicine and 
Hygiene. 2006;100:521-526. DOI: 
10.1016/j.trstmh.2005.08.012
[11] Özbel Y, Töz ÖS. Leishmaniosis. 
In: Özcel MA, editor. Tıbbi Parazit 
Hastalıkları. 1.Baskı ed. İzmir: Meta 
Basım Matbacılık Hizmetleri; 2007. 
pp. 198-230
[12] Achtman JC, Ellis DL, Saylors 
B, Boh EE. Cutaneous leishmaniasis 
caused by Leishmania (Viannia) 
panamensis in 2 travelers. JAAD Case 
Reports. 2016;2:95-97. DOI: 10.1016/j.
jdcr.2015.11.018
[13] Marsden PD. Mucosal 
leishmaniasis (“espundia” Escomel, 
1911). Transactions of the Royal 
Society of Tropical Medicine and 
Hygiene. 1986;80:859-876. DOI: 
10.1016/0035-9203(86)90243-9
[14] Calvopiña M, Martinez L, 
Hashiguchi Y. Cutaneous leishmaniasis 
“chiclero’s ulcer” in subtropical Ecuador. 
The American Journal of Tropical 
Medicine and Hygiene. 2013;89:195-196. 
DOI: 10.4269/ajtmh.12-0690
[15] Lainson R, Shaw JJ, Ready PD, 
Miles MA, Póvoa M. Leishmaniasis in 
Brazil: XVI. Isolation and identification 
of Leishmania species from sandflies, 
wild mammals and man in north Para 
12
Current Topics in Neglected Tropical Diseases
state, with particular reference to L. 
braziliensis guyanensis causative agent 
of “pian-bois”. Transactions of the 
Royal Society of Tropical Medicine 
and Hygiene. 1981;75:530-536. DOI: 
10.1016/0035-9203(81)90192-9
[16] Llanos-Cuentas EA, Roncal N, 
Villaseca P, Paz L, Ogusuku E, Pérez JE, 
et al. Natural infections of Leishmania 
peruviana in animals in the Peruvian 
Andes. Transactions of the Royal 
Society of Tropical Medicine and 
Hygiene. 1999;93:15-20. DOI: 10.1016/
S0035-9203(99)90163-3
[17] Ovallos FG, Silva YR, Fernandez 
N, Gutierrez R, Galati EA, Sandoval 
CM. The sandfly fauna, anthropophily 
and the seasonal activities of Pintomyia 
spinicrassa (Diptera: Psychodidae: 
Phlebotominae) in a focus of cutaneous 
leishmaniasis in northeastern Colombia. 
Memórias do Instituto Oswaldo Cruz. 
2013;108:297-302. DOI: 10.1590/
S0074-02762013000300007
[18] WHO. Neglected Tropical 
Diseases, Hidden Successes, Emerging 
Opportunities. Geneva: World Health 
Organization; 2009. p. 59
[19] Aversi-Ferreira RAGMF, Galvão 
JD, da Silva SF, Cavalcante GF, da Silva 
EV, Bhatia-Dey N, et al. Geographical 
and environmental variables of 
leishmaniasis transmission. In: Claborn 
DM, editor. Leishmaniasis—Trends in 
Epidemiology, Diagnosis and Treatment. 
InTech; 2014. DOI: 10.5772/57546
[20] Pigott DM, Bhatt S, Golding N, 
Duda KA, Battle KE, Brady OJ, et al. 
Global distribution maps of the 
leishmaniases. eLife. 2014;3. DOI: 
10.7554/eLife.02851
[21] Ready PD. Epidemiology of visceral 
leishmaniasis. Clinical Epidemiology. 
2014;6:147-154. DOI: 10.2147/CLEP.
S44267
[22] Amro A, Hamdi S, Lemrani M, 
Idrissi M, Hida M, Rhajaoui M, et al. 
Moroccan Leishmania infantum: Genetic 
diversity and population structure as 
revealed by multi-locus microsatellite 
typing. PLoS ONE. 2013;8:e77778. DOI: 
10.1371/journal.pone.0077778
[23] Kavur H, Eroglu F, Evyapan G, 
Demirkazik M, Alptekin D, Koltas 
IS. Entomological survey for sand fly 
fauna in imamoglu province (cutaneous 
leishmaniasis endemic region) of 
Adana, Turkey. Journal of Medical 
Entomology. 2015;52:813-818. DOI: 
10.1093/jme/tjv064
[24] Kasap OE, Belen A, Kaynas S,  
Simsek FM, Biler L, Ata N, et al. 
Activity patterns of sand fly (Diptera: 
Psychodidae) species and comparative 
performance of different traps in an 
endemic cutaneous leishmaniasis focus 
in cukurova plain, Southern Anatolia, 
Turkey. Acta Veterinaria. 2008;78: 
327-335. DOI: 10.2754/avb200978020327
[25] Silva Jde A, Araújo Ide M, 
Pavanetti LC, Okamoto LS, Dias 
M. Visceral leishmaniasis and 
pregnancy in renal transplanted 
patient: Case report. Jornal Brasileiro 
de Nefrologia. 2015;37:268-270. DOI: 
10.5935/0101-2800.20150041
[26] de Silva AA, Silva Filho ÁPE, Sesso 
Rde C, Esmeraldo Rde M, de Oliveira 
CM, Fernandes PF, et al. Epidemiologic, 
clinical, diagnostic and therapeutic 
aspects of visceral leishmaniasis in 
renal transplant recipients: Experience 
from thirty cases. BMC Infectious 
Diseases. 2015;25(15):96. DOI: 10.1186/
s12879-015-0852-9
[27] Fishman JA. Infections in 
immunocompromised hosts and organ 
transplant recipients: Essentials. Liver 
Transplantation. 2011;17(Suppl 3): 
S34-S37. DOI: 10.1002/lt.22378
[28] Alvar J, Aparicio P, Aseffa A, 
Den Boer M, Canavate C, et al. The 
relationship between leishmaniasis and 
13
Epidemiology and Ecology of Leishmaniasis
DOI: http://dx.doi.org/10.5772/intechopen.86359
AIDS: The second 10 years. Clinical 
Microbiology Reviews. 2008;21:334-359. 
DOI: 10.1128/CMR.00061-07
[29] van Griensven J, Ritmeijer K, Lynen 
L, Diro E. Visceral leishmaniasis as 
an AIDS defining condition: Towards 
consistency across WHO guidelines. 
PLoS Neglected Tropical Diseases. 
2014;17(8):e2916. DOI: 10.1371/journal.
pntd.0002916
[30] Croft SL, Coombs GH. Leish-
maniasis—Current chemotherapy 
and recent advances in the search for 
novel drugs. Trends in Parasitology. 
2003;19:502-508
[31] Mittal MK, Rai S, Ashutosh, 
Ravinder, Gupta S, Sundar S, et al. 
Characterization of natural antimony 
resistance in Leishmania donovani 
isolates. The American Journal of 
Tropical Medicine and Hygiene. 
2007;76(4):681-688
[32] Rijal S, Ostyn B, Uranw S, Rai K, 
Bhattarai NR, Dorlo TP, et al. Increasing 
failure of miltefosine in the treatment of 
Kala-azar in Nepal and the potential role 
of parasite drug resistance, reinfection, 
or noncompliance. Clinical Infectious 
Diseases. 2013;56(11):1530-1538. DOI: 
10.1093/cid/cit102
[33] Mondelaers A, Sanchez-Cañete 
MP, Hendrickx S, Eberhardt E, Garcia-
Hernandez R, Lachaud L, et al. Genomic 
and molecular characterization 
of miltefosine resistance in 
Leishmania infantum strains with 
either natural or acquired resistance 
through experimental selection of 
intracellular amastigotes. PLoS ONE. 
2016;11(4):e0154101. DOI: 10.1371/
journal.pone.0154101
[34] Srivastava S, Mishra J, Gupta AK, 
Singh A, Shankar P, Singh S. Laboratory 
confirmed miltefosine resistant cases 
of visceral leishmaniasis from India. 
Parasites & Vectors. 2017;10(1):49. DOI: 
10.1186/s13071-017-1969-z
[35] Cojean S, Houze ÂS, Haouchine 
D, Huteau F, Lariven S, Hubert 
V, et al. Leishmania resistance to 
miltefosine associated with genetic 
marker. Emerging Infectious Diseases. 
2012;18(4):704-706. DOI: 10.3201/
eid1804.110841
[36] Verma A, Bhandari V, Deep 
DK, Sundar S, Dujardin JC, Singh 
R, et al. Transcriptome profiling 
identifies genes/pathways associated 
with experimental resistance to 
paromomycin in Leishmania donovani. 
International Journal for Parasitology: 
Drugs and Drug Resistance. 
2017;7(3):370-377. DOI: 10.1016/j.
ijpddr.2017.10.004
[37] Deep DK, Singh R, Bhandari V, 
Verma A, Sharma V, Wajid S, et al. 
Increased miltefosine tolerance in 
clinical isolates of Leishmania donovani 
is associated with reduced drug 
accumulation, increased infectivity 
and resistance to oxidative stress. 
PLoS Neglected Tropical Diseases. 
2017;11(6):e0005641. DOI: 10.1371/
journal.pntd.0005641
[38] Ponte-Sucre A, Gamarro F, Dujardin 
J-C, Barrett MP, LoÂpez-VeÂlez R, 
Garcõ Âa-HernaÂndez R, et al. Drug 
resistance and treatment failure in 
leishmaniasis: A 21st century challenge. 
PLoS Neglected Tropical Diseases. 
2017;11(12):e0006052. DOI: 10.1371/
journal.pntd.0006052
[39] Hefnawy A, Berg M, Dujardin JC, 
De Muylder G. Exploiting knowledge on 
Leishmania drug resistance to support 
the quest for new drugs. Trends in 
Parasitology. 2017;33(3):162-174. DOI: 
10.1016/j.pt.2016.11.003
[40] Rastrojo A, García-Hernández 
R, Vargas P, Camacho E, Corvo L, 
Imamura H, et al. Genomic and 
transcriptomic alterations in Leishmania 
donovani lines experimentally resistant 
to antileishmanial drugs. International 
Journal for Parasitology: Drugs and 
14
Current Topics in Neglected Tropical Diseases
Drug Resistance. 2018;8(2):246-264. 
DOI: 10.1016/j.ijpddr.2018.04.002
[41] Kotton CN. Travel and 
transplantation: Travel-related diseases 
in transplant recipients. Current 
Opinion in Organ Transplantation. 
2012;17:594-600. DOI: 10.1097/
MOT.0b013e328359266b
[42] Lund PV. Fortsatte Bemaerkninger 
over BrasiliensuddÖ de Dyrskagning. 
Kongelige Danske Videnskabernes 
Selskabs Naturvidenskabeligeog 
Mathematiske Afhandlinger. 
1842;9:1-136
[43] Lainson R, Elizabeth FR. Lutzomyia 
longipalpis and the eco-epidemiology 
of American visceral leishmaniasis, 
with particular reference to Brazil: A 
review. Memórias do Instituto Oswaldo 
Cruz. 2005;100:811-827. DOI: 10.1590/
S0074-02762005000800001
[44] Capelli G. Asymptomatic and 
symptomatic dogs in endemic areas, 
their role in the epidemiology of 
canine leishmaniosis. In: The 2nd 
Canine Vector-Borne Disease (CVBD) 
Symposium; Mazara del Vallo, Sicily, 
Italy; 2007. pp. 58-63. Available 
from: http://www.cvbd.org/static/
documents/digest/CVBD_Easy-
to-digest_no_1_leishmaniosis.pdf 
[Accessed: 14 june 2016]
[45] Baneth G, Koutinas AF, Solano-
Gallego L, Bourdeau P, Ferrer L. Canine 
leishmaniosis—New concepts and 
insights on an expanding zoonosis: 
Part one. Trends in Parasitology. 
2008;24:324-330. DOI: 10.1016/j.
pt.2008.04.001
[46] Banuls AL, Hide M, Prugnolle F. 
Leishmania and the leishmaniases: A 
parasite genetic update and advances 
in taxonomy, epidemiology and 
pathogenicity in humans. Advances in 
Parasitology. 2007;64:1-109-455-458. 
DOI: 10.1016/S0065-308X(06)64001-3
[47] Sherlock IA. Ecological interactions 
of visceral leishmaniasis in the state of 
Bahia, Brazil. Memórias do Instituto 
Oswaldo Cruz. 1996;91:671-683. DOI: 
10.1590/S0074-02761996000600003
[48] Lainson R. The American 
leishmaniases: Some observations 
on their ecology and epidemiology. 
Transactions of the Royal 
Society of Tropical Medicine and 
Hygiene. 1983;77:569-596. DOI: 
10.1016/0035-9203(83)90185-2
[49] El-Adhami B. Isolation of 
Leishmania from a black rat in the 
Baghdad area, Iraq. The American 
Journal of Tropical Medicine and 
Hygiene. 1976;25:759-761
[50] Inceboz T, Lambrecht FY, 
Eren MŞ, Girginkardeşler N, Bekiş 
R, Yilmaz O, et al. Evaluation of 
131I-pentamidine for scintigraphy of 
experimentally Leishmania tropica-
infected hamsters. Journal of Drug 
Targeting. 2014;22:416-420. DOI: 
10.3109/1061186X.2013.878943
[51] Pourmohammadi B, Motazedian 
MH, Kalantari M. Rodent infection with 
Leishmania in a new focus of human 
cutaneous leishmaniasis, in northern 
Iran. Annals of Tropical Medicine and 
Parasitology. 2008;102:127-133. DOI: 
10.1179/136485908X252223
[52] Pozzio E, Gradoni L, Bettini S, 
Gramiccia M. Leishmaniasis in Tuscani 
(Italy) V. Further isolation of leishmania 
from Rattusrattusin the province of 
Grosseto. Annals of Tropical Medicine 
and Parasitology. 1981;75:393-395 doi.
org/10.5169/seals-312840
[53] Papadogiannakis E, Spanakos G, 
Kontos V, Menounos PG, Tegos N, 
Vakalis N. Molecular detection of 
Leishmania infantum in wild rodents 
(Rattus norvegicus) in Greece. Zoonoses 
and Public Health. 2010;57:e23-e25. 
DOI: 10.1111/j.1863-2378.2009.01264.x
15
Epidemiology and Ecology of Leishmaniasis
DOI: http://dx.doi.org/10.5772/intechopen.86359
[54] Ashford RW. The leishmaniases 
as model zoonoses. Annals of Tropical 
Medicine and Parasitology. 1997;91: 
693-701. DOI: 10.1080/00034989760428
[55] Lukes J, Mauricio IL, Schönian G, 
Dujardin JC, Soteriadou K, Dedet JP, 
et al. Evolutionary and geographical 
history of the Leishmania donovani 
complex with are vision of current 
taxonomy. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2007;104:9375-9380. 
DOI: 10.1073/pnas.0703678104
[56] Deane LM. Leishmaniose visceral 
no Brasil. Serviço Nacional de 
Educação Sanitária. 1956:1-162. 
Available from: http://www.
scielo.br/scielo.php?script=sci_
nlinks&ref=000065&pid=S0102-311X20
0800120002400008&lng=en
[57] Deane LM. Epidemiologia e 
profilaxia do calazaramericano. 
Revista Brasileira de Malariologia. 
1958;10:431-450. Available from: http://
www.scielo.br/scielo.php?script=sci_
nlinks&ref=000022&pid=S0102-311X20
0800070002600001&lng=en
[58] Alencar JE. Profilaxia do calazar 
no Ceará Brasil. Revista do Instituto 
de Medicina Tropical de São Paulo. 
1961;3:175-180. Available from: 
http://www.scielosp.org/scieloOrg/
php/reflinks.php?refpid=S0034-
8910199000050000300003&lng=pt&p
id=S0034-89101990000500003
[59] World Health Organization (WHO). 
Control of Leishmaniasis. Tech Rep 
Series. 793, Geneva; 1990. 158 pp
[60] Alencar JE. Kala-azar in Brazil. 
Scientific Reports of the Istituto 
Superiore di Sanità. 1962;2:116-123
[61] Apostila UFPE. Available from: 
http://www.ufpe.br/biolmol/
Leishmanioses-Apostila_on_line/
infogerais.htm. 2013;16:99-109
[62] Mayrink W, Genero O, Silva JCF, 
Costa RT, Tafuri WL, Toledo VPCP, 
et al. Phase I and II open clinical trials 
of a vaccine against Leishmania chagasi 
infection in dogs. Memórias do Instituto 
Oswaldo Cruz. 1996;91:695-697. DOI: 
10.1590/S0074-02761996000600006
[63] Genaro O, Pinto JA, Costa CA, 
França-Silva JC, Costa RT, Silva JC, 
et al. Phase III randomized double blind 
clinical trial on the efficacy of a vaccine 
against canine visceral leishmaniasis 
in urban area of Montes Claros, 
MG, Brazil. Memórias do Instituto 
Oswaldo Cruz. 1996;91(Suppl):166. 
Available from: http://memorias.
ioc.fiocruz.br/component/k2/
item/5932-immunology-212-phase-iii-
randomized-double-blind-clinical-trial-
on-the-efficacy-of-a-vaccine-against-
canine-visceral-leishmaniasis-in-urban-
area-of-montes-claros-mg-brazil
[64] Silva VO, Borja-Cabrera GP, Correia 
Pontes NN, Souza EP, Luz KG, Palatinik 
M, et al. A Phase III trial of efficacy 
of the FML-vaccine against canine 
calazar in an endemic area of Brasil (São 
Gonçalo do Amarante, RN). Vaccine. 
2000;19:1082-1092. DOI: 10.1016/
S0264-410X(00)00339-X
